HDAC8 and cardiac hypertrophy: We investigated the effects of different concentrations of PCI34051 (3, 10, and 30 mg/kg bodyweight/day), an HDAC8 selective inhibitor, on concomitant cardiac hypertrophy using the TAC-induced heart failure mouse model.